News und Analysen
Humana Ranks #1 for Customer Satisfaction for Mail Order in J.D. Power Pharmacy Study for Third Year in a Row
Humana Pharmacy, a division of Humana Inc. (NYSE: HUM), has been named the best in Mail Order Pharmacy customer satisfaction in the J.D. Power 2020 U.S. Pharmacy Study. It’s the third consecutive
Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020
Pfizer Inc. (NYSE: PFE) announced today that it will be holding its rescheduled Investor Day virtually over two days: Monday, September 14, 2020 from 1:00 p.m. EDT to approximately 4:00 p.m. EDT
Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020
Pfizer Inc. (NYSE: PFE) announced today that it will be holding its rescheduled Investor Day virtually over two days: Monday, September 14, 2020 from 1:00 p.m. EDT to approximately 4:00 p.m. EDT
MorphoSys: Anlegern gefällt der Ausblick nicht, aber...
Erst am vergangenen Wochenende konnte das deutsche Biotechunternehmen MorphoSys (WKN: 663200) einen großen Erfolg verbuchen, nämlich die FDA-Zulassung des Krebsmittels Monjuvi. Daraufhin machte die
MorphoSys: Anlegern gefällt der Ausblick nicht, aber...
Erst am vergangenen Wochenende konnte das deutsche Biotechunternehmen MorphoSys (WKN: 663200) einen großen Erfolg verbuchen, nämlich die FDA-Zulassung des Krebsmittels Monjuvi. Daraufhin machte die
NanoString and Bio-Techne Announce Offering of RNAscope Reagents Validated for Use With the GeoMx Digital Spatial Profiler
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and Bio-Techne (NASDAQ:TECH), a global life sciences company
Simulations Plus Announces Pricing of $100 Million Underwritten Offering of Common Stock
Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products and services for the pharmaceutical
FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed
FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company
STAAR Surgical Reports Second Quarter 2020 Results
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the
Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported second quarter 2020 financial results and recent business highlights.
“We are very excited about our global
Kezar Life Sciences Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its
Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today treatment of the first patient in the Phase 2 portion of the LIO-1 trial evaluating the combination of lucitanib, Clovis’ investigational
LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer
Pfizer Inc. (NYSE:PFE) today announced that the Phase 3 CROWN study of LORBRENA® (lorlatinib) in people with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell
LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer
Pfizer Inc. (NYSE:PFE) today announced that the Phase 3 CROWN study of LORBRENA® (lorlatinib) in people with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell
Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the virtual Canaccord Genuity Global Growth
Novavax: Nachbörsliche Räuberpistole!
Gestern Abend kam es nachbörslich zu einer wilden Berg- und Talfahrt bei der Aktie des US-amerikanischen Biotechunternehmens Novavax (WKN: A2PKMZ). Der Grund hierfür wirkt kurios.
Zunächst einmal
Evotec: Vorstand streckt Fühler nach Antisense-Startup aus
Evotec (WKN: 566480) geht seine nächste strategische Partnerschaft ein. So wurde, wie heute vermeldet, mit dem Marburger Next-Generation-Wirkstoffforscher Secarna Pharmaceuticals eine Kooperation im
Xencor Reports Second Quarter 2020 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial
Acadia Healthcare Reports Second Quarter 2020 Results
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the second quarter ended June 30, 2020.
The Company reported revenue of $750.3 million for the second quarter
Transgene Receives $22.2 Million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that it has raised $22.2 million (€ 19
Premier Inc. ProvideGx® Program Partners with Somerset Pharma to Stabilize Pricing, Enhance Competition for Sulfamethoxazole/Trimethoprim
Premier Inc. (NASDAQ: PINC), through its ProvideGx® program, has partnered with Somerset Pharma, LLC., to supply sulfamethoxazole/trimethoprim, an antibiotic combination used to treat respiratory
Simulations Plus Announces Proposed Underwritten Public Offering
Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products and services for the pharmaceutical
Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at